<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125306</url>
  </required_header>
  <id_info>
    <org_study_id>GLAUCOMA/XAL EASE 1</org_study_id>
    <nct_id>NCT01125306</nct_id>
  </id_info>
  <brief_title>Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the
      Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect
      instillation.

      Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year
      according to consumption data drawn from the Clalit Health Services database, will use the
      Xal-Ease device for a year. The device is expected to reduce consumption of bottles and
      result in saving money for both patients and medical care providers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consumption of Xalatan/Xalacom bottles per year per patient.</measure>
    <time_frame>12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterizing the optimal conditions for proper usage of the Xal-Ease device</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xal-Ease</intervention_name>
    <description>Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.</description>
    <other_name>Xal-Ease as a Pfizer-Pharmacia device.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with glaucoma or hypertension treated with Xalatan/Xalacom who have consumed
             more than one bottle per month within a year prior to initiation of the study.

        Exclusion Criteria:

          -  Patients younger than 18 years,

          -  Patients with severe manual disabilities,

          -  Patients with impaired cognition and mentality.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ophthalmology department, Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronit Nesher, MD</last_name>
      <phone>972-9747555</phone>
      <phone_ext>2774</phone_ext>
      <email>nesher.ronit@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Ronit Nesher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Semes L, Shaikh AS. Evaluation of the Xal-Ease latanoprost delivery system. Optometry. 2007 Jan;78(1):30-3.</citation>
    <PMID>17208672</PMID>
  </reference>
  <results_reference>
    <citation>Nordmann JP, Baudouin C, Bron A, Denis P, Rouland JF, Sellem E, Renard JP. Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol. 2009 Nov-Dec;19(6):949-56.</citation>
    <PMID>19882583</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug consumption</keyword>
  <keyword>The Xal-Ease device</keyword>
  <keyword>Patient's compliance</keyword>
  <keyword>Using a novel Pfizer-Pharmacia device to facilitate the Xalatan/Xalacom instillation and to avoid loss of eye drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

